I have started to research hostile take overs and found this article that sounds close to what is going on:
https://blog.nacdonline.org/posts/watch-hosti...eover-2021
The employee stock compensation I think was a big part of Cytodyn defense against hostile takeovers. Now that it has been reversed, we are in a vulnerable situation. Be very aware of what is presented from these 5% investors, if they have a plan for a buyout that is less than current market cap., they will be planning on actively scaring away investors until they own enough at a cheap enough price to make the offer good for them. Us non 5% investors could be left with very little. I am not sure how this works yet, but we should all reader has this process so we can see these actions as the develop for what they are. There is no way this 5% group is going away or in this for all of our best interest. They will present a plan designed to attract as many believers as possible to get what their goal is.
I think most here have asked why BP has not bought us out or partnered, not even a rumor has had much weight. Most of us can agree that BP is not going to let cytodyn just walk away with a chunk of there revenue. Cytodyn is close enough to doing that and if the discussions that have taken place set a tone of no reasonable deal is possible, BP will do what it can to end our chances. I can see a BP talking to investment groups to work out a plan that enriches them while the bod and loyal investors are left in the dark. I feel there is more to the reason we go to fife for funding and Paulson is not part of it. There is a significant alignment already in place prior to this 13d.
I can be confident that Nader is 100% ignoring it and focused on running Cytodyn as if it does not exist. He is the type of person to focus on what is within his control and disregard the actions of others that he can’t control. It is good in a way, because we all need leronlimab to go a far as fast as possible. My worry is that the BLA will get parts filed but the fda will simply find more issues out of the blue. The longhaulers data will be compelling but will be only P2 data so it will be only able to form a future P3 trial. There could be a lack of public interest in the p2 data. The BTD for the cancer trial could go either way, but it is totally in the fda’s court. I am worried that the pressure to get the sp lower for this 5% group will be huge and the actual great trial data will not be able to overcome it.
Let’s not be naive, the 5% group is going to put out a plan designed to attract and divide, it will be bashing the current mgmt and paint a great future. Be very careful, they are not interest in saving lives or a fair deal for us all, they are in it for themselves. If you did not join them, you are their enemy and they have no concern for what you think is the best path forward.
https://blog.nacdonline.org/posts/watch-hosti...eover-2021
The employee stock compensation I think was a big part of Cytodyn defense against hostile takeovers. Now that it has been reversed, we are in a vulnerable situation. Be very aware of what is presented from these 5% investors, if they have a plan for a buyout that is less than current market cap., they will be planning on actively scaring away investors until they own enough at a cheap enough price to make the offer good for them. Us non 5% investors could be left with very little. I am not sure how this works yet, but we should all reader has this process so we can see these actions as the develop for what they are. There is no way this 5% group is going away or in this for all of our best interest. They will present a plan designed to attract as many believers as possible to get what their goal is.
I think most here have asked why BP has not bought us out or partnered, not even a rumor has had much weight. Most of us can agree that BP is not going to let cytodyn just walk away with a chunk of there revenue. Cytodyn is close enough to doing that and if the discussions that have taken place set a tone of no reasonable deal is possible, BP will do what it can to end our chances. I can see a BP talking to investment groups to work out a plan that enriches them while the bod and loyal investors are left in the dark. I feel there is more to the reason we go to fife for funding and Paulson is not part of it. There is a significant alignment already in place prior to this 13d.
I can be confident that Nader is 100% ignoring it and focused on running Cytodyn as if it does not exist. He is the type of person to focus on what is within his control and disregard the actions of others that he can’t control. It is good in a way, because we all need leronlimab to go a far as fast as possible. My worry is that the BLA will get parts filed but the fda will simply find more issues out of the blue. The longhaulers data will be compelling but will be only P2 data so it will be only able to form a future P3 trial. There could be a lack of public interest in the p2 data. The BTD for the cancer trial could go either way, but it is totally in the fda’s court. I am worried that the pressure to get the sp lower for this 5% group will be huge and the actual great trial data will not be able to overcome it.
Let’s not be naive, the 5% group is going to put out a plan designed to attract and divide, it will be bashing the current mgmt and paint a great future. Be very careful, they are not interest in saving lives or a fair deal for us all, they are in it for themselves. If you did not join them, you are their enemy and they have no concern for what you think is the best path forward.
11
1
